Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 3.06
HSKA's Cash to Debt is ranked higher than
50% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. HSKA: 3.06 )
Ranked among companies with meaningful Cash to Debt only.
HSKA' s Cash to Debt Range Over the Past 10 Years
Min: 0.27  Med: 0.69 Max: No Debt
Current: 3.06
Equity to Asset 0.56
HSKA's Equity to Asset is ranked lower than
57% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. HSKA: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
HSKA' s Equity to Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.57 Max: 0.78
Current: 0.56
0.02
0.78
F-Score: 7
Z-Score: 2.34
M-Score: -2.36
WACC vs ROIC
7.83%
8.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 6.80
HSKA's Operating margin (%) is ranked higher than
65% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. HSKA: 6.80 )
Ranked among companies with meaningful Operating margin (%) only.
HSKA' s Operating margin (%) Range Over the Past 10 Years
Min: -1.83  Med: 3.10 Max: 6.71
Current: 6.8
-1.83
6.71
Net-margin (%) 4.07
HSKA's Net-margin (%) is ranked higher than
63% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. HSKA: 4.07 )
Ranked among companies with meaningful Net-margin (%) only.
HSKA' s Net-margin (%) Range Over the Past 10 Years
Min: -1.53  Med: 2.05 Max: 42.28
Current: 4.07
-1.53
42.28
ROE (%) 7.36
HSKA's ROE (%) is ranked higher than
63% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. HSKA: 7.36 )
Ranked among companies with meaningful ROE (%) only.
HSKA' s ROE (%) Range Over the Past 10 Years
Min: -2.49  Med: 4.84 Max: 140.27
Current: 7.36
-2.49
140.27
ROA (%) 4.01
HSKA's ROA (%) is ranked higher than
68% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. HSKA: 4.01 )
Ranked among companies with meaningful ROA (%) only.
HSKA' s ROA (%) Range Over the Past 10 Years
Min: -1.49  Med: 2.30 Max: 61.02
Current: 4.01
-1.49
61.02
ROC (Joel Greenblatt) (%) 23.72
HSKA's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. HSKA: 23.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HSKA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5.69  Med: 11.48 Max: 23.5
Current: 23.72
-5.69
23.5
Revenue Growth (3Y)(%) 2.20
HSKA's Revenue Growth (3Y)(%) is ranked lower than
62% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. HSKA: 2.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HSKA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.9  Med: 1.15 Max: 10.4
Current: 2.2
-16.9
10.4
EBITDA Growth (3Y)(%) 1.00
HSKA's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. HSKA: 1.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HSKA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.9  Med: -25.80 Max: 27.7
Current: 1
-63.9
27.7
EPS Growth (3Y)(%) 0.30
HSKA's EPS Growth (3Y)(%) is ranked higher than
51% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. HSKA: 0.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HSKA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -92.2  Med: -35.55 Max: 7.6
Current: 0.3
-92.2
7.6
» HSKA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

HSKA Guru Trades in Q1 2015

Jim Simons 168,280 sh (+28.87%)
Mario Gabelli 52,400 sh (-1.13%)
» More
Q2 2015

HSKA Guru Trades in Q2 2015

Mario Gabelli 52,400 sh (unchged)
Jim Simons 165,180 sh (-1.84%)
» More
Q3 2015

HSKA Guru Trades in Q3 2015

Jim Simons 215,426 sh (+30.42%)
Mario Gabelli 50,400 sh (-3.82%)
» More
Q4 2015

HSKA Guru Trades in Q4 2015

Mario Gabelli 50,200 sh (-0.40%)
» More
» Details

Insider Trades

Latest Guru Trades with HSKA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 60.19
HSKA's P/E(ttm) is ranked lower than
86% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.20 vs. HSKA: 60.19 )
Ranked among companies with meaningful P/E(ttm) only.
HSKA' s P/E(ttm) Range Over the Past 10 Years
Min: 0.5  Med: 33.01 Max: 549.09
Current: 60.19
0.5
549.09
Forward P/E 30.30
HSKA's Forward P/E is ranked lower than
85% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.45 vs. HSKA: 30.30 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 60.71
HSKA's PE(NRI) is ranked lower than
84% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. HSKA: 60.71 )
Ranked among companies with meaningful PE(NRI) only.
HSKA' s PE(NRI) Range Over the Past 10 Years
Min: 0.5  Med: 33.47 Max: 604
Current: 60.71
0.5
604
P/B 3.91
HSKA's P/B is ranked lower than
72% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. HSKA: 3.91 )
Ranked among companies with meaningful P/B only.
HSKA' s P/B Range Over the Past 10 Years
Min: 0.22  Med: 1.27 Max: 75.45
Current: 3.91
0.22
75.45
P/S 2.47
HSKA's P/S is ranked lower than
58% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.13 vs. HSKA: 2.47 )
Ranked among companies with meaningful P/S only.
HSKA' s P/S Range Over the Past 10 Years
Min: 0.12  Med: 0.70 Max: 2.71
Current: 2.47
0.12
2.71
POCF 176.00
HSKA's POCF is ranked lower than
99% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.17 vs. HSKA: 176.00 )
Ranked among companies with meaningful POCF only.
HSKA' s POCF Range Over the Past 10 Years
Min: 2.36  Med: 22.04 Max: 496.33
Current: 176
2.36
496.33
EV-to-EBIT 34.87
HSKA's EV-to-EBIT is ranked lower than
76% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.89 vs. HSKA: 34.87 )
Ranked among companies with meaningful EV-to-EBIT only.
HSKA' s EV-to-EBIT Range Over the Past 10 Years
Min: -150.8  Med: 20.30 Max: 172
Current: 34.87
-150.8
172
EV-to-EBITDA 21.50
HSKA's EV-to-EBITDA is ranked lower than
75% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.88 vs. HSKA: 21.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
HSKA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -63.4  Med: 11.70 Max: 59.1
Current: 21.5
-63.4
59.1
Shiller P/E 35.36
HSKA's Shiller P/E is ranked higher than
53% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.56 vs. HSKA: 35.36 )
Ranked among companies with meaningful Shiller P/E only.
HSKA' s Shiller P/E Range Over the Past 10 Years
Min: 7.39  Med: 17.63 Max: 254.5
Current: 35.36
7.39
254.5
Current Ratio 2.13
HSKA's Current Ratio is ranked lower than
58% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. HSKA: 2.13 )
Ranked among companies with meaningful Current Ratio only.
HSKA' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.91 Max: 5.19
Current: 2.13
1.03
5.19
Quick Ratio 1.22
HSKA's Quick Ratio is ranked lower than
77% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. HSKA: 1.22 )
Ranked among companies with meaningful Quick Ratio only.
HSKA' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 1.03 Max: 4.4
Current: 1.22
0.56
4.4
Days Inventory 95.81
HSKA's Days Inventory is ranked lower than
51% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. HSKA: 95.81 )
Ranked among companies with meaningful Days Inventory only.
HSKA' s Days Inventory Range Over the Past 10 Years
Min: 82.09  Med: 106.38 Max: 109.49
Current: 95.81
82.09
109.49
Days Sales Outstanding 51.43
HSKA's Days Sales Outstanding is ranked higher than
66% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. HSKA: 51.43 )
Ranked among companies with meaningful Days Sales Outstanding only.
HSKA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.35  Med: 48.74 Max: 55.37
Current: 51.43
41.35
55.37
Days Payable 46.25
HSKA's Days Payable is ranked lower than
57% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. HSKA: 46.25 )
Ranked among companies with meaningful Days Payable only.
HSKA' s Days Payable Range Over the Past 10 Years
Min: 26.98  Med: 36.54 Max: 46.37
Current: 46.25
26.98
46.37

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.81
HSKA's Dividend Yield is ranked lower than
76% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. HSKA: 0.81 )
Ranked among companies with meaningful Dividend Yield only.
HSKA' s Dividend Yield Range Over the Past 10 Years
Min: 0.79  Med: 2.22 Max: 3.73
Current: 0.81
0.79
3.73
Yield on cost (5-Year) 0.80
HSKA's Yield on cost (5-Year) is ranked lower than
74% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.58 vs. HSKA: 0.80 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
HSKA' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.79  Med: 2.22 Max: 3.73
Current: 0.8
0.79
3.73
3-Year Average Share Buyback Ratio -6.30
HSKA's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.80 vs. HSKA: -6.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HSKA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.6  Med: -3.70 Max: 1.8
Current: -6.3
-29.6
1.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 6.02
HSKA's Price/Tangible Book is ranked lower than
58% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.76 vs. HSKA: 6.02 )
Ranked among companies with meaningful Price/Tangible Book only.
HSKA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.3  Med: 2.20 Max: 261.43
Current: 6.02
0.3
261.43
Price/Projected FCF 4.89
HSKA's Price/Projected FCF is ranked lower than
85% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.06 vs. HSKA: 4.89 )
Ranked among companies with meaningful Price/Projected FCF only.
HSKA' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.57  Med: 1.00 Max: 20.11
Current: 4.89
0.57
20.11
Price/Median PS Value 3.49
HSKA's Price/Median PS Value is ranked lower than
97% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.96 vs. HSKA: 3.49 )
Ranked among companies with meaningful Price/Median PS Value only.
HSKA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 1.19 Max: 18.7
Current: 3.49
0.23
18.7
Price/Graham Number 4.01
HSKA's Price/Graham Number is ranked lower than
72% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.44 vs. HSKA: 4.01 )
Ranked among companies with meaningful Price/Graham Number only.
HSKA' s Price/Graham Number Range Over the Past 10 Years
Min: 0.2  Med: 1.84 Max: 28.09
Current: 4.01
0.2
28.09
Earnings Yield (Greenblatt) (%) 2.86
HSKA's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. HSKA: 2.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HSKA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 4.20 Max: 21.2
Current: 2.86
0.6
21.2
Forward Rate of Return (Yacktman) (%) -2.44
HSKA's Forward Rate of Return (Yacktman) (%) is ranked lower than
82% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. HSKA: -2.44 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HSKA' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -86.8  Med: -2.60 Max: 7.5
Current: -2.44
-86.8
7.5

More Statistics

Revenue(Mil) $99
EPS $ 0.58
Beta0.80
Short Percentage of Float3.29%
52-Week Range $20.00 - 40.29
Shares Outstanding(Mil)6.59

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 103 120 133 147
EPS($) 0.70 0.90 1.15 1.45
EPS without NRI($) 0.70 0.90 1.15 1.45

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Heska Corp was founded as Paravax, Inc. in 1988 and conducted research on vaccines to prevent infections by parasites. The Company develops, manufactures, markets, sells and supports veterinary products. The Company's core focus is on the canine and feline companion animal health markets where it provides high value products. The Company's business is comprised of two reportable segments: Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. The Core Companion Animal Health segment includes mainly for canine and feline use, blood testing instruments and supplies as well as single use products and services such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. These products are sold directly to veterinarians by the Company as well as through distribution relationships. The Other Vaccines, Pharmaceuticals and Products segment includes private label vaccine and pharmaceutical production, mainly for cattle but also for other animals including small mammals. All OVP products are sold by third parties under third party labels. It provides line of veterinary diagnostic and other instruments. Its line of veterinary instruments includes the following: Blood Chemistry; Hematology; Blood Gases and Electrolytes; and IV Pumps. The DRI-CHEM 4000 Veterinary Chemistry Analyzer is a robust system that uses dry slide technology for blood chemistry and electrolyte analysis and has the ability to run 22 tests at a time with a single blood sample. The HEMATRUE Veterinary Hematology Analyzer is a blood analyzer that measures such key parameters as white blood cell count, red blood cell count, platelet count and hemoglobin levels in animals. The Element POC Blood Gas & Electrolyte Analyzer is a handheld, wireless analyzer which delivers rapid blood gas, electrolyte, metabolite, and basic blood chemistry testing. EPOC features test cards with room temperature storage which can provide results with less than 100 uL of sample as well as WiFi and Bluetooth connectivity. The VET/IV 2.2 infusion pump is a compact, affordable IV pump that allows veterinarians to easily provide regulated infusion of fluids, drugs or nutritional products for their patients. Allergy is common in companion animals, and it has been estimated to affect approximately 10% to 15% of dogs. The Company sells kits to conduct blood testing using its ALLERCEPT Definitive Allergen Panels to third-party veterinary diagnostic laboratories outside of the United States. It has veterinary diagnostic laboratories in Loveland, Colorado and Fribourg, Switzerland which both provide blood testing using its ALLERCEPT Definitive Allergen Panels. Its competitors include: IDEXX Laboratories, Inc., Abaxis, Inc. and Synbiotics Corporation. The Company may be or subject to extensive regulation by governmental authorities in the United States, including the USDA and the FDA, and by similar agencies in other countries.
» More Articles for HSKA

Headlines

Articles On GuruFocus.com
My 5 Favorite High Beta Health Care Dividend Stocks Aug 02 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
Heska Corporation: Strong Balance Sheet and Dividend Yield Do Not Compensate for Difficult Business Dec 13 2012 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 5,000 Shares Jun 01 2010 
Heska Corp. (HSKA) CEO Robert B Grieve buys 6,500 Shares May 21 2010 
Weekly CFO Buys Highlight: ZixIt, Global Defense Technology and Systems, FelCor Lodging Trust, Heska Mar 07 2010 
Heska Corp. (HSKA) CFO Jason A Napolitano buys 1,000 Shares Mar 01 2010 
Weekly CFO Buys Highlight: Heska Corp., Apollo Investment Corp., EXACT Sciences Corp., Innospec Inc. Feb 28 2010 
Heska Corp. (HSKA) President and COO Michael J Mcginley buys 12,290 Shares Feb 26 2010 

More From Other Websites
Heska's Upgrade Is in Keeping With Uptrend Dec 30 2015
Can the Rally in Heska (HSKA) Shares Continue? Dec 30 2015
HESKA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Dec 29 2015
5 Best-Performing Russell 2000 Stocks of 2015 Dec 29 2015
Heska (HSKA) Looks Good: Stock Adds 5% in Session Dec 28 2015
Heska Corp. Earnings Analysis: Q3, 2015 By the Numbers Dec 23 2015
HESKA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 16 2015
Should Heska Corporation (HSKA) Be On Your Radar Now? Dec 11 2015
HESKA CORP Financials Dec 08 2015
A Look Inside the Chart, Technical Insights - Research on Trupanion, Tobira Therapeutics, Old Second... Dec 07 2015
Do Hedge Funds Love Rocket Fuel Inc (FUEL)? Dec 01 2015
A Look Inside the Chart, Technical Insights - Research on Trupanion, Tobira Therapeutics, Old Second... Nov 27 2015
Here is What Hedge Funds Think About Regional Management Corp (RM) Nov 26 2015
HESKA CORP Files SEC form 8-K, Change in Directors or Principal Officers Nov 24 2015
Can Heska (HSKA) Stock Continue to Grow Earnings? Nov 18 2015
HESKA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and... Nov 16 2015
Illumina (ILMN) Set to Enter the Coveted S&P 500, Stock Up Nov 13 2015
Heska Corp.: Strong price momentum but will it sustain? Nov 13 2015
HESKA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 12 2015
Strength Seen in Heska (HSKA): Stock Moves 11.5% Higher Nov 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK